ERBB2 and breast cancer: The present study demonstrates the ability of VCX to cause a concentration-dependent cell growth inhibition in three breast cancer cell lines that pose different molecular subtypes, MCF-7 (ER+), SKBR-3 (HER-2+), and MDA-MB-231 (TNBC).